We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CBOE:CBOECboe Global Markets, Inc. Analysis

Data as of 2026-06-12 - not real-time

$294.91

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

CBOE is trading above its 20‑day moving average while the 20‑day SMA remains above the 50‑day SMA, signaling a short‑term bullish bias, yet the MACD histogram is negative and the MACD line sits below its signal, hinting at weakening momentum. RSI is hovering around the mid‑low 40s, suggesting the stock is not yet oversold but also not in overbought territory. Volatility over the past 30 days is markedly high, exceeding 50%, and beta is slightly negative, indicating limited correlation with broader market moves. The current price is well above the DCF‑derived fair value and the trailing P/E ratio outpaces the industry average, pointing to an overvalued valuation profile. Dividend yield sits just under 1% with a modest payout ratio below 25%, supporting dividend sustainability.
Recent SEC approval to launch pre‑ and post‑market trading for select equity options, slated for July, could broaden CBOE’s product suite and attract additional order flow, while the expansion of the DJX options suite adds further revenue avenues. Strong operating margins, robust cash generation, and a solid balance sheet underpin the fundamentals, but the elevated valuation and high short‑term volatility temper enthusiasm. The blend of growth‑oriented initiatives and stable dividend policy suggests a nuanced outlook that leans toward caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Negative MACD histogram despite bullish SMA positioning
  • Elevated 30‑day volatility
  • Upcoming extended trading hours could boost volume but may cause short‑term price adjustments

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong operating and free cash flow supporting dividend sustainability
  • Diversified revenue streams across options, equities, futures and FX
  • Valuation still above fair value, limiting upside potential

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Persistent overvaluation relative to DCF and peers
  • High volatility and modest beta indicating uncertain price stability
  • Competitive pressure in exchange and data services markets

Key Metrics & Analysis

Financial Health

Revenue Growth6.50%
Profit Margin25.77%
P/E Ratio25.2
ROE25.14%
ROA10.59%
Debt/Equity29.49
P/B Ratio5.7
Op. Cash Flow$2.8B
Free Cash Flow$1.0B
Industry P/E16.8

Technical Analysis

TrendBullish
RSI40.3
Support$269.96
Resistance$371.18
MA 20$321.74
MA 50$318.14
MA 200$273.88
MACDBearish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

Fair Value$172.76
Target Price$326.93
Upside/Downside10.86%
GradeOvervalued
TypeBlend
Dividend Yield0.97%

Risk Assessment

Beta-0.24
Volatility56.84%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.